GoldenGolden
Rock Springs Capital

Rock Springs Capital

Rock Springs Capital is a Baltimore-based company founded in 2013.

Rock Springs Capital is a Baltimore, Maryland based hedge fund established in 2013 that specializes in the healthcare and biotechnology sector. The firm is a long/short equity fund.

Rock Springs Capital advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.

Investment

Rock Springs Capital has made investments in Inozyme, Fusion Pharmaceutical, Imara, Vedanta Biosciences, Akero Therapeutics, Aprea, Mirum Pharmaceuticals and Galera Therapeutics.

Their exits include BeiGene, Invitae, Galera Therapeutics, Spark Therapeutics, Adaptive Biotechnologies, Ra Pharmaceuticals, AveXis, Menlo Therapeutics, Kaleido BioSciences, ZAI Lab, Ardelyx and Synlogic.

Funds

Rock Springs Capital has raised a total of $1.5 billion across 2 funds, their latest being Rock Springs Capital Fund. This fund was announced on October 5, 2017 and raised a total of $1.1 billion. They announced their Rock Springs Capital Offshore Fund on September 11, 2017 with a raised total of $395.9 million.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
March 22, 2021

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.